Compare CHMI & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | APLT |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 18.0M |
| IPO Year | 2013 | 2019 |
| Metric | CHMI | APLT |
|---|---|---|
| Price | $2.64 | $0.13 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $2.75 | $1.25 |
| AVG Volume (30 Days) | 221.1K | ★ 8.6M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $40,202,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | $31.73 | $66.67 |
| P/E Ratio | $140.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.17 | $0.10 |
| 52 Week High | $3.68 | $1.50 |
| Indicator | CHMI | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 68.02 | 27.06 |
| Support Level | $2.47 | $0.10 |
| Resistance Level | $2.62 | $0.13 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 92.96 | 17.28 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.